The results showed that targeting CD47 and angiogenesis could be a potential strategy for treating bladder cancer, and anti-angiogenic drugs could improve the efficacy of anti-CD47 immunotherapy. The gene discussed is CD47; the disease is urinary bladder carcinoma.